The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Altum Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; HUTCHMED (I); Ipsen; Lilly; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche; Sanofi; SERVIER; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors.
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Douglas Reznick
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Guardant Health
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Guardant Health
 
Steven Y. Liu
Employment - Gilead Sciences
 
Niels Reinmuth
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Sabeen Fatima Mekan
No Relationships to Disclose
 
Riddhi Patel
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Michelle Ding
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Luis Paz-Ares
No Relationships to Disclose